1 week Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates Zacks

Xilio Therapeutics (XLO) delivered earnings and revenue surprises of 9.09% and 23.72%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?